Lv4
700 积分 2025-08-29 加入
FLOT vs CROSS Among Patients With Pathological Complete Response in Esophageal Adenocarcinoma
3天前
已完结
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer
3天前
已完结
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
4天前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
4天前
已完结
The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist)
12天前
已关闭
Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer
12天前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
12天前
已完结
Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)
12天前
已完结
PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC
13天前
已完结
PT2.13.02 Multi-Cycle Low-Dose Radiotherapy Reshapes Immunochemotherapy for ES-SCLC: The SPUR Phase II Trial
23天前
已关闭
皖公网安备34019202002308
